Latest Commercialization News

Mercury NZ Limited reported a 10% decline in earnings for FY2025 amid challenging generation conditions but is pressing ahead with significant renewable energy investments and raised dividends.

HMC Capital reported a robust FY25 with a 51% rise in operating EPS and a 47% jump in assets under management to $18.7 billion, driven by expansion across multiple funds management divisions.

HMC Capital has reported a record FY25 with pre-tax operating earnings soaring 74% and EPS up 51%, driven by strong asset growth and diversified platform success. The company sets a confident FY26 outlook targeting sustained organic growth and stable dividends.

HMC Capital Limited reported a record FY25 profit of $265.2 million, driven by strategic acquisitions and growth in digital infrastructure and energy transition sectors. The company also declared a consistent dividend and strengthened its balance sheet with an increased undrawn debt facility.

The Takeovers Panel has declined to intervene in the ongoing takeover tussle for PointsBet Holdings, allowing shareholders to weigh competing offers from MIXI Australia and betr Entertainment.

Peak Rare Earths Limited has entered a scheme of arrangement with Shenghe Resources (Singapore) Pte. Ltd., valuing the company at approximately A$158 million. The scheme offers Peak shareholders a cash consideration of no less than A$0.359 per share, representing a 199% premium to the last closing price.

ClearVue Technologies has responded to ASX concerns after its CEO described previous project pipeline announcements as ‘fairy tales,’ affirming prior disclosures were accurate despite some project setbacks.

Lake Resources has tapped its At-the-Market facility to raise A$1.575 million, aiming to fund key development stages of its flagship Kachi lithium project in Argentina.

Lake Resources has successfully raised up to A$12 million through a strongly supported placement, bolstering its financial position to advance the Kachi lithium project in Argentina.

Rhythm Biosciences has launched a $3.75 million placement alongside an offer of over 52 million new options, all contingent on shareholder approval. The move aims to bolster working capital as the company advances its cancer diagnostic products.

FBR Limited invites eligible shareholders to participate in a $1 million Share Purchase Plan at a 23.1% discount, aiming to fund key robotic projects and repay debt.

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.